New combo therapy aims to rescue failing hearts without transplant

NCT ID NCT06965504

Not yet recruiting Disease control Sponsor: Abiomed Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a heart pump (Impella 5.5) along with standard heart failure medications can help people with severe heart failure and shock recover without needing a heart transplant or permanent artificial heart. About 250 adults with weak hearts (ejection fraction 40% or less) will be enrolled. The goal is to see if this combined approach reduces death, hospital stays, and the need for heart replacement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiogenic shock cardiovascular disorder heart disorder heart failure Shock, Cardiogenic systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOGENIC SHOCK HEART FAILURE REDUCED EJECTION FRACTION HEART FAILURE

Contacts and locations

Locations

Abbott Northwestern

Minneapolis, Minnesota, 555407, United States
Atrium Health

Charlotte, North Carolina, 28204, United States
Centennial Medical Center

Nashville, Tennessee, 32703, United States
Duke University

Durham, North Carolina, 27710, United States
Rutgers-Robert Wood Johnson Medical School

New Brunswick, New Jersey, 08901, United States
Tampa General Hospital

Tampa, Florida, 33606, United States
University of Pennsylvania Health System

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.